ImmunoScape
  • Our Science
  • Our Pipeline
  • News & Resources
  • About Us
  • Contact us
Articles
Jan 19, 2023

Nextgen TCR therapies can improve diagnosis and treatment regimens

Our CEO and co-founder, Choon-Peng (Choon) Ng recently spoke with BioSpectrum Asia about how our unique Deep Immunomics and machine learning platforms can discover and...

$
Sep 14, 2022

ImmunoScape To Present at the 7th Annual CAR-TCR Summit

ImmunoScape To Present at the 7th Annual CAR-TCR Summit San Diego, California and Singapore – September 14, 2022 – ImmunoScape, a pre-clinical biotechnology company...

$
Sep 14, 2022

ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors

ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors   Anzu Partners led the $14M financing round with...

$
Mar 21, 2022

Read our latest publication together with NAIAD and Johns Hopkins University on the T cell response to the mutations found in the omicron variant of SARS-CoV-2

ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University. Read our paper here: Minimal Crossover between Mutations Associated...

$
Feb 16, 2022

ImmunoScape Inks Licensing Deal with Pure MHC to Advance Development of Novel TCR- Based Therapies

SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 – ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of...

$
Jul 28, 2021

ImmunoScape Appoints Renowned Immuno-Oncology Expert Adrian Woolfson, BM BCh, PhD, to Board of Directors

SINGAPORE and SAN DIEGO – July 28, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune...

$
Jun 29, 2021

ImmunoScape Expands its Executive and Scientific Teams to Extend Use of its Deep Immunomics Platform into Drug Discovery

SINGAPORE and SAN DIEGO – June 29, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune...

$
Apr 14, 2021

ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery

SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human...

$
Mar 30, 2021

T cells recognize recent SARS-CoV-2 variants (NIAID, Johns Hopkins University, & ImmunoScape Collaboration)

ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University to better understand if the CD8+ T-cell responses from COVID-19...

$
1 2 3 Next
immuno scape footer logo
  • Follow
  • Follow
  • Follow
  • Follow
ImmunoScape, Global Headquarters:

ImmunoScape Pte Ltd
1 Scotts Road #24-10
Singapore 228208

ImmunoScape, USA Headquarters:

ImmunoScape, Inc.
11575 Sorrento Valley Road, Suite 204
San Diego, CA 92121, United States

Copyright © 2023 ImmunoScape.

Privacy Policy